Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0848332 (Spots)
 453 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Recently, we reported the proteome analysis of a human hepatocellular carcinoma cell line, HCC-M (Electrophoresis 2000, 21, 1787-1813), using two-dimensional gel electrophoresis (2-DE) and matrix assisted laser desorption/ionization-time of flight-mass spectrometry (MALDI-TOF-MS). From a total of 408 unique spots excised from the 2-DE gel, 301 spots yielded good MALDI spectra. Out of these, 272 spots had matches returned from the database search leading to the identification of these proteins. Here, we report the results on the identification of the remaining 29 spots using nanoelectrospray ionization-tandem mass spectrometry (nESI-MS/MS). First, "peptide tag sequencing" was performed to obtain partial amino acid sequences of the peptides to search the SWISS-PROTand NCBI nonredundant protein databases. Spots that were still not able to find any matches from the databases were subjected to de novo peptide sequencing. The tryptic peptide sequences were used to search for homologues in the protein and nucleotide databases with the NCBI Basic Local Alignment Search Tool (BLAST), which was essential for the characterization of novel or post-translationally modified proteins. Using this approach, all the 29 spots were unambiguously identified. Among them, phosphotyrosyl phosphatase activator (PTPA), RNA-binding protein regulatory subunit, replication protein A 32 kDa subunit (RP-A) and N-acetylneuraminic acid phosphate synthase were reported to be cancer-related proteins.
 ...
PMID:Proteome analysis of a human heptocellular carcinoma cell line, HCC-M: an update. 1154 12

The purpose of this study is to present a variety of measures that quantify equity in cancer outcomes, demonstrate how the measures perform in various cancer types, and identify counties, or Bright Spots, that meet the criteria of those measures. Using county-level age adjusted death rates for 2007-2016 from the National Center for Health Statistics, we determined counties that had both equitable and optimal outcomes for the black and white death rates across five cancer types, lung/bronchus, prostate, breast, colorectal, and liver cancers. The number of counties that met the criteria ranged from 0 to 442 depending on cancer type and measure used, and prostate and male liver cancer consistently had the lowest number of Bright Spots with a maximum of 3 counties meeting the most lenient criteria. This study presents several ways to examine equity, using rate ratios and standard error measures, in cancer mortality outcomes. It highlights areas with positive progress towards equity and areas potential need for equity-focused cancer control planning. Examining local areas of positive deviance can inform cancer control programming and planning around health equity.
 ...
PMID:Finding 'Bright Spots': Using Multiple Measures to Examine Local-Area Racial Equity in Cancer Death Outcomes. 3307 38